These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17150003)

  • 1. Kidney cancer therapy: new perspectives and avenues.
    Alexandrescu DT; Dasanu CA
    Expert Opin Pharmacother; 2006 Dec; 7(18):2481-93. PubMed ID: 17150003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic therapy of metastatic renal cell carcinoma].
    Autenrieth M; Heidenreich A; Gschwend JE
    Urologe A; 2006 May; 45(5):594-9. PubMed ID: 16622645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy and targeted therapy combinations in renal cancer.
    McDermott DF
    Curr Clin Pharmacol; 2011 Aug; 6(3):207-13. PubMed ID: 21827391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents.
    Porta C; Paglino C; Imarisio I; Bonomi L
    ScientificWorldJournal; 2007 Apr; 7():837-49. PubMed ID: 17619768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.
    Porta C; Toscani I; Czarnecka AM; Szczylik CA
    Expert Opin Biol Ther; 2017 Feb; 17(2):151-162. PubMed ID: 27960591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.
    Zarrabi K; Wu S
    Curr Oncol Rep; 2018 Apr; 20(5):41. PubMed ID: 29611002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current state of systemic therapy of metastatic renal cell carcinoma].
    Merseburger AS; Waalkes S; Kuczyk MA
    Urologe A; 2009 Sep; 48(9):983-4, 986, 988-9. PubMed ID: 19669118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the therapy of renal cancer.
    Sonpavde G; Hutson TE
    Expert Opin Biol Ther; 2007 Feb; 7(2):233-42. PubMed ID: 17250461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2017 Feb; 14(2):76-78. PubMed ID: 28031562
    [No Abstract]   [Full Text] [Related]  

  • 11. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma.
    Ficarra V; Novara G
    Nat Rev Urol; 2010 Feb; 7(2):63-4. PubMed ID: 20145660
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy.
    Aparicio LMA; Fernandez IP; Cassinello J
    Clin Transl Oncol; 2017 Oct; 19(10):1175-1182. PubMed ID: 28409322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for renal carcinoma: theoretical basis and current standard of care.
    Vasey PA
    Br J Clin Pharmacol; 2000 Dec; 50(6):521-9. PubMed ID: 11136291
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
    Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
    J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D; Culine S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical treatment of renal cell carcinoma].
    Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
    Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.